LUPIN-GLUCAGON DIN 02568969
Health Canada record
| Active ingredient(s) | GLUCAGON 1 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intramuscular; Intravenous; Subcutaneous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | H04AA01 GLUCAGON |
| Original market date | |
| Current status date | 10-Jun-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Lupin Pharma Canada Limited — licence 102119, currently licensed, last inspection rating C (2025-07-22).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GLUCAGON
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02492415 | BAQSIMI | AMPHASTAR PHARMACEUTICALS, INC. | Powder | GLUCAGON 3 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37689 | 2026-06-10 | New Drug Submission (NDS) |
International API supply for GLUCAGON
4 active FDA Drug Master Files.
Request a quote for LUPIN-GLUCAGON